Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

17.28USD
23 May 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.28
Open
$17.31
Day's High
$17.35
Day's Low
$17.00
Volume
1,048,399
Avg. Vol
1,545,070
52-wk High
$23.33
52-wk Low
$2.36

Latest Key Developments (Source: Significant Developments)

Amarin Reports Q1 Adjusted Non-GAAP Loss Per Share $0.05
Wednesday, 1 May 2019 

May 1 (Reuters) - Amarin Corporation PLC ::REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.05 EXCLUDING ITEMS.Q1 REVENUE $73.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $67.3 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.Q1 GAAP LOSS PER SHARE $0.07.  Full Article

Amarin Submits Supplemental New Drug Application To U.S. FDA
Thursday, 28 Mar 2019 

March 28 (Reuters) - Amarin Corporation PLC ::AMARIN SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO U.S. FDA SEEKING NEW INDICATION FOR VASCEPA (ICOSAPENT ETHYL) TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS BASED ON LANDMARK REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY.OPERATING UNDER ASSUMPTION THAT SNDA WILL BE REVIEWED ON A STANDARD REVIEW CLOCK OF TEN MONTHS RESULTING IN A PDUFA DATE NEAR END OF JAN 2020.  Full Article

American Diabetes Association Issues Critical Update To Standards Of Medical Care In Diabetes
Wednesday, 27 Mar 2019 

March 27 (Reuters) - American Diabetes Association::AMERICAN DIABETES ASSOCIATION ISSUES CRITICAL UPDATE TO STANDARDS OF MEDICAL CARE IN DIABETES.UPDATED SECTION 10 OF LIVING STANDARDS OF CARE TO INCLIDE RECOMMENDATION THAT ICOSAPENT ETHYL BE CONSIDERED FOR PATIENTS WITH ASCVD.  Full Article

Amarin Reports Q4 Adj Non-GAAP Loss Per Share Of $0.09
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.09 EXCLUDING ITEMS.Q4 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.Q4 GAAP LOSS PER SHARE $0.11.REAFFIRMS THAT EARLIER GUIDANCE HAS NOT CHANGED.SAYS NET PRODUCT REVENUE FOR THREE MONTHS ENDED DECEMBER 31, 2018 AND 2017 WAS $77.1 MILLION AND $53.5 MILLION, RESPECTIVELY.  Full Article

Amarin Reports Q3 Loss Per Share Of $0.08
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.06 EXCLUDING ITEMS.Q3 EARNINGS PER SHARE VIEW $-0.10 -- THOMSON REUTERS I/B/E/S.Q3 GAAP LOSS PER SHARE $0.08.QTRLY NET PRODUCT REVENUE FOR THREE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017 WAS $55.0 MILLION AND $47.1 MILLION, RESPECTIVELY.PLANS TO SUBMIT SUPPLEMENTAL NDA IN EARLY 2019 SEEKING AN EXPANDED INDICATION FOR VASCEPA IN UNITED STATES.  Full Article

Amarin Reports Q2 GAAP Loss Of $0.12 Per Share
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.10 EXCLUDING ITEMS.Q2 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.Q2 GAAP LOSS PER SHARE $0.12.QTRLY NET PRODUCT REVENUE $52.5 MILLION VERSUS $44.9 MILLION.  Full Article

Amarin Says Settlement Agreement Provides That Co Will Pay Teva $2 Mln
Thursday, 24 May 2018 

May 24 (Reuters) - Amarin Corporation PLC ::AMARIN CORPORATION SAYS SETTLEMENT AGREEMENT WITH TEVA PROVIDES THAT CO WILL PAY TEVA $2 MILLION - SEC FILING.AMARIN CORPORATION PLC - OTHER TERMS OF SETTLEMENT AGREEMENT WITH TEVA ARE CONFIDENTIAL.  Full Article

Amarin estimates net product revenue for Q1 to be about $43 mln
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Amarin Corporation PLC ::AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES.ESTIMATES THAT NET PRODUCT REVENUE FOR ITS FIRST FISCAL QUARTER IS LIKELY TO BE APPROXIMATELY $43 MILLION.‍WITH RESPECT TO FY 2018 NET PRODUCT REVENUE EXPECTATIONS, CONTINUES TO BELIEVE ON TRACK TO ACHIEVE PRODUCT REVENUE OF AT LEAST $230 MILLION.​.  Full Article

Amarin Announces Proposed Public Offering Of American Depositary Shares
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Amarin Corporation Plc ::AMARIN ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES.AMARIN CORPORATION PLC - ‍ANNOUNCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES​.AMARIN CORPORATION PLC - TO USE NET PROCEEDS FROM OFFERING TO EXPAND MEDICAL EDUCATION AND MARKET AWARENESS INITIATIVES.  Full Article

Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Amarin Corp Plc ::AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK.AMARIN CORPORATION PLC SEES ‍UNAUDITED FULL-YEAR 2017 NET PRODUCT REVENUE ESTIMATED BETWEEN $177 AND $180 MILLION​.AMARIN - ‍WITHOUT ADJUSTMENT FOR IMPACT OF REDUCE-IT RESULTS, CO ESTIMATES 2018 NET PRODUCT REVENUE FROM VASCEPA WILL GROW TO ABOUT $230 MILLION​.AMARIN - ‍ESTIMATES IN EACH QUARTER OF 2018 NET PRODUCT REVENUE SHOULD GROW APPROXIMATELY 30% OR MORE AS COMPARED TO SAME QUARTER IN 2017​.AMARIN CORPORATION PLC - ‍ESTIMATES THAT ITS NET PRODUCT REVENUE IN Q1 2018 WILL BE BETWEEN $45 AND $48 MILLION​.AMARIN CORPORATION PLC - ‍ANTICIPATES THAT Q2 2018 RESULTS WILL REBOUND WITH NET PRODUCT REVENUE ANTICIPATED IN Q2 2018 OF $55 MILLION OR MORE​.  Full Article

Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study

March 18 A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday.